GlassScriptPhysician profile
Muhammad I Akhtar
NPI 1740266022
$4,415.47
in general payments reported to CMS, 2019-2025
33 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $975 · 2021: $402 · 2022: $454 · 2023: $350 · 2024: $827 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.01 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $840.54 | 2020-2022 | |
| Abbvie INC. | $795.85 | 2021-2025 | Ubrelvy |
| Neurocrine Biosciences, INC. | $304.45 | 2022-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $262.61 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $223.10 | 2019-2021 | |
| Ucb, INC. | $181.72 | 2023-2025 | Briviact, Nayzilam |
| Lilly USA, LLC | $157.46 | 2020-2025 | Kisunla, Emgality, Amyvid |
| Mdd US Operations, LLC | $152.01 | 2023-2025 | Gocovri, Gocovri |
| Teva Pharmaceuticals USA, INC. | $148.31 | 2020-2022 | |
| Pfizer INC. | $147.24 | 2023-2025 | |
| Emd Serono, INC. | $130.74 | 2022 | |
| Biogen, INC. | $119.40 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Eisai INC. | $113.61 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $112.65 | 2019-2023 | Nuplazid |
| Amgen INC. | $93.46 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $91.57 | 2024-2025 | Dysport |
| Sunovion Pharmaceuticals INC. | $88.37 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $87.21 | 2019-2025 | Crexont, Rytary |
| Novartis Pharmaceuticals Corporation | $75.67 | 2019-2020 | |
| Abbott Laboratories | $46.33 | 2021-2023 | Infinity |
| Avanir Pharmaceuticals, INC. | $25.24 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $24.38 | 2021 | |
| Kyowa Kirin, INC. | $22.83 | 2024 | Nourianz |
| Novo Nordisk INC | $22.27 | 2023 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $20.10 | 2024 | Nuedexta |
| Aucta Pharmaceuticals, INC. | $20.07 | 2025 | Motpoly Xr |
| Astrazeneca Pharmaceuticals LP | $17.03 | 2025 | Tezspire |
| Celgene Corporation | $16.96 | 2025 | Zeposia |
| Genzyme Corporation | $16.87 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Chiesi USA, INC. | $15.76 | 2025 | Cleviprex |
| Alexion Pharmaceuticals, INC. | $13.53 | 2024 | Ultomiris |
| Adamas Pharmaceuticals, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.